Pharma Chiefs Warn Europe Is Losing Drug Innovation Race to US and China

The board chairs of nine of Europe’s largest pharmaceutical companies—including AstraZeneca, GSK, Novo Nordisk, Novartis, Roche, and Sanofi—have issued a collective warning to European governments, arguing that the continent is rapidly losing ground to the United States and China in life sciences. In a joint intervention alongside Boehringer Ingelheim, Chiesi, and Ipsen, the executive leaders warned that without swift policy action to encourage innovation and protect intellectual property, critical research, capital investment, and drug development will continue to migrate overseas. The group highlighted that Europe’s current regulatory environment and pricing pressures are disincentivising cutting-edge medical research compared to competing global markets.

For European citizens, the relocation of pharmaceutical research directly affects early access to new medical treatments. When clinical trials and drug development move to the US or Asia, European patients often wait longer for novel therapies while local hospitals miss out on clinical trial funding. Beyond healthcare, life sciences represent one of the continent's major high-tech export industries. A sustained shift in investment away from Europe threatens high-skilled scientific jobs, reduces tax revenues for national budgets, and leaves the continent increasingly dependent on foreign supply chains for essential medicines.

In Brussels, public warnings from industrial heavyweights are a standard feature of major legislative battles. The warning arrives as the EU navigates the biggest overhaul of its general pharmaceutical legislation in twenty years. At the heart of the dispute is regulatory data protection—the period during which drugmakers retain exclusive rights to their research before generic competitors can enter the market. The European Commission initially proposed shortening standard exclusivity periods to incentivize companies to launch products across all 27 member states simultaneously. While EU officials view this as a tool to balance healthcare equity between wealthier and poorer member states, industry leaders consider it a regulatory penalty. It is a classic institutional standoff: Brussels attempting to engineer market fairness through administrative levers, while global companies threaten to vote with their feet.

The intervention adds friction to negotiations over the pharmaceutical package, which must pass through the ordinary legislative procedure—the standard EU lawmaking process where the European Parliament and national ministers in the Council must agree on identical text. Member state governments with strong domestic pharmaceutical sectors are expected to push for stronger protection for intellectual property during upcoming council negotiations. Meanwhile, EU lawmakers face the challenge of balancing affordable, equal drug access for patients with keeping research capital inside European borders.